NEW YORK (GenomeWeb) – Mission Bio said today that it has raised $30 million in a Series B financing round led by Agilent Technologies, Cota Capital, LAM Capital, and Mayfield, bringing its total financing to more than $50 million.
The South San Francisco, California startup has been developing droplet microfluidic single-cell DNA analysis technology and plans to use the funds to scale its Tapestri platform, which it launched last year. Mission Bio currently sells the platform along with a targeted research-use only panel focused on acute myeloid leukemia and a kit for customers to design their own panels.
"We can beat cancer with more effective, dynamic therapies, but we first need to precisely understand its biology, starting with the varying genetic composition of each and every cancerous cell," Charlie Silver, Mission Bio CEO, said in a statement. "With the Tapestri platform, we can track every cell, every mutation, to better guide treatments and save patient lives," he added.
Aside from expanding within the blood cancer research space, Mission Bio also plans to extend into CRISPR applications.
"The Tapestri platform's unique quality control capabilities are strengthening our CRISPR R&D programs," Darlene Solomon, senior vice president and chief technology officer at Agilent, said in the statement.